Released Nov 5, 2026, before the open
10-Q filed Nov 5, 2026, 36 days after period end · 0001628280-26-070618
Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with moderately-to-severely active Crohn's disease.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $1.00M | $3.00M | $686.00K |
| Net Income | -$25.20M | -$10.06M | -$16.68M | -$27.54M |
Shattuck Labs, Inc. · CIK 1680367 · Engraved from SEC EDGAR
| EPS Diluted | -$0.14 | -$0.14 | -$0.33 | -$0.65 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Shattuck Labs reported a net loss of $25.2 million, or $0.14 per basic and diluted share, for the quarter ended September 30, 2026, compared with a net loss of $10.1 million for the same quarter of 2025.¶2
Research and development expenses were $21.6 million and general and administrative expenses were $5.5 million for the quarter ended September 30, 2026, compared with $7.6 million and $4.1 million a year earlier.¶3¶4
Cash and cash equivalents and short-term investments were $196.3 million as of September 30, 2026, which the company expects to fund operations into 2029.¶5¶6
Shattuck initiated the RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease, randomizing approximately 232 patients, and expects to initiate the RECEPTIVE-HS1 Phase 2 trial in hidradenitis suppurativa in the fourth quarter of 2026.¶1¶7¶8